Travere Therapeutics Posts 144% Year-Over-Year Growth with $322M Filspari Sales
Travere’s Filspari generated $322 million in 2025, up 144% year-over-year, contributing to total net product sales of $410.5 million and Q4 sales of $126.6 million. Reimbursement now covers 96% of patients and the FDA’s SNDA action date for FSGS expansion is set for April 13.
1. 2025 Sales Performance
Travere posted $410.5 million in net product sales for 2025, driven by Filspari’s $322 million revenue, marking a 144% lift over the prior year and $126.6 million in Q4 sales.
2. Growth Drivers
Filspari adoption benefited from updated clinical guidelines, growing physician confidence, and reimbursement coverage now extending to 96% of the patient population.
3. Upcoming Milestones
The FDA target action date for the Filspari SNDA in FSGS is April 13, while Travere has resumed site activation for its Phase 3 Harmony study of Pegtobatinase and expanded its field team to over 100 representatives.